Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$122.85+4.47%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put INCY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance slipped notably this past month, though still top-half.
View ThesisRevenue growth is accelerating — up about 25% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 19%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 15% growth a year, above the roughly 4% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIncyte's late-stage pipeline has to keep compounding to justify the price. Revenue growth is slowing, falling from 38% to 14% year over year. The latest quarter beat estimates, though revenue growth decelerated. The stock trades at 47 times earnings versus a 21 times peer median. The market is pricing in more growth than we forecast. Recent financial performance slipped notably this past month. Peer multiples imply a price about 15% below where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-11-04. INCY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering INCY (as of Nov 2026).
Based on 15 Wall Street analysts offering 12-month price targets for INCY in the last 4 months.
Continue this research
Compare INCY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| INCY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put INCY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Clinical collaboration supports pipeline development, but the announcement alone provides no efficacy or late-stage progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $122.85
The last 12 months of price, then the range of analyst 12-month targets from today’s $122.85.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Pipeline updates support advancement of late-stage studies.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
New data supports advancement of late-stage pipeline.
Advances: Increase total net sales and Hematology and Oncology sales
Sales growth aligns with management's goal for increased net sales.
Advances: Advance late-stage pipeline with multiple Phase 3 studies
Positive pivotal Phase 2 results advance zilurgisertib toward late-stage development.
Advances: Increase total net sales and Hematology and Oncology sales
Raised Opzelura outlook and sales guidance support growth objectives.
Rating downgrade may impact investor sentiment and valuation.
Threatens: Increase total net sales and Hematology and Oncology sales
Significant full-year sales guidance miss threatens expected growth.